Drug Profile
ASP 8232
Alternative Names: ASP8232Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Eye disorder therapies
- Mechanism of Action AOC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic macular oedema; Diabetic nephropathies
Most Recent Events
- 27 Jul 2018 Discontinued - Phase-II for Diabetic macular oedema in USA due to strategic prioritisation (PO) (Astellas Pharma pipeline, July 2018)
- 27 Jul 2018 Discontinued - Phase-II for Diabetic nephropathies (Adjunctive treatment) in Italy, Spain, Poland, Netherlands, Germany, United Kingdom, Hungary, Denmark, Czech Republic, Belgium due to strategic prioritisation (PO) (Astellas Pharma pipeline, July 2018)
- 27 Jul 2018 Discontinued - Phase-II for Diabetic nephropathies in Moldova, Romania, Bulgaria due to strategic prioritisation (PO) (Astellas Pharma pipeline, July 2018)